glp 1 agonist eye side effects A potentially blinding condition is a very rare effect of the GLP-1 receptor semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Semaglutide Tied to Increased Risk
Description
Interestingly, it also stimulates insulin secretion from -cells, but with much lower potency than GLP-1 with the mechanism potentially due to the weak binding of glucagon at GLP-1 receptor site [11]
Jorsal A, Kistorp C, Holmager P, et al
Back AAAS EurekAlert (18 Dec 2023) 'Toronto study identifies new concepts for GLP-1 action in the brain, the 2023 Science magazine breakthrough of the year'
[DOI] [PubMed] [Google Scholar] 392.Pyke C., Heller R.S., Kirk R.K., Orskov C., Reedtz-Runge S., Kaastrup P
Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, et al
It does not identify endotoxins, residual solvents, or trace metals
